(Image source: Photo.com)
On April 9, 2024, Yisheng Biotech announced that the interim data of the Phase III clinical trial of the Pika-adjuvant rabies vaccine has achieved breakthrough positive results. The rabies vaccine, which is based on pickup adjuvant technology, is designed for rapid immune protection, potentially shortening the standard immunization schedule of three to four weeks to just one week.
The Pikaadjuvant Rabies Vaccine is an iterative product that adopts the core R&D achievement of Yisheng Biotech - Pikaadjuvant technology. This novel double-stranded RNA adjuvant can significantly improve the immunogenicity and protective efficacy of vaccines by inducing multiple mechanisms such as interferon production. Among the first 900 patients enrolled, the neutralization serology conversion rate on day 7 was twice as high in the Pikaadjuvant rabies vaccine group as in the control group. At the same time, the increase in immunogenicity did not come at the cost of increased side effects, and the tolerability remained good.
The traditional rabies vaccine of Yisheng Biotech has been marketed, and its sales are increasing year by year. According to the data, the sales in 2021 will be 184 million yuan, which will increase to 502 million yuan in 2022 and 687 million yuan in 2023. It is foreseeable that with the launch of the pickup adjuvant rabies vaccine, the performance of Yisheng Biotech will usher in a new growth point.
According to the data of Qichamao, Liaoning Yisheng Biopharmaceutical Co., Ltd. (hereinafter referred to as Yisheng Bio) was established in 1994.It is a global professional biopharmaceutical company integrating R&D, production and sales, committed to the development of innovative biotherapeutics against tumors and viral infections.
In recent years, the rabies vaccine industry in mainland China has made great progress, the production technology and quality of vaccines have been continuously improved, the number of production enterprises has increased, and the market competition has become increasingly fierce. At the same time, the government has also stepped up the supervision of rabies vaccine to ensure the safety and effectiveness of the vaccine. The scope of vaccination is also expanding, so that more pets and humans can be vaccinated in time to effectively prevent the occurrence of rabies.
Vaccines prevent rabies with a high case fatality rate
Rabies is a virulent viral zoonotic disease with a case fatality rate of nearly 100%. According to the Chinese Center for Disease Control and Prevention, there were 130 cases of rabies in China in 2021, and all patients unfortunately died, with a high case fatality rate. From January to February 2021, the number of rabies cases in China was 20, of which 18 unfortunately died.
Once bitten and scratched by rabies or other mad animals, you need to get 1 dose of rabies vaccine as soon as possible and complete several doses within the specified time. After vaccination, it can stimulate the body to produce immunity against rabies virus, which is used to prevent rabies.
In 2020, rabies vaccines were the most varied
In 2020, the number of rabies vaccines issued in batches reached 786 million of all vaccines in China, ranking first. Influenza vaccine and diphtheria-pertussis vaccine were the second and third largest batches, with 688 million and 682 million doses, respectively.
With the importance of pet health and the continuous expansion of the pet market, the demand for rabies vaccine is gradually increasing. At the same time, the mainland government's support for the field of pet health care is also increasing, providing a good policy environment for the development of the rabies vaccine industry. With the continuous progress of science and technology, the research and development technology of rabies vaccine is also improving, and there will be more innovative products and technology applications in the rabies vaccine industry in the future, injecting new vitality into the development of the industry. Therefore, it is foreseeable that the prospects of the rabies vaccine industry in mainland China will continue to improve and have great development potential.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "In-depth Research and Investment Strategic Planning Analysis Report of China's Vaccine Industry" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certificate, IPO consulting/fundraising and investment feasibility study, and specialized and special new small giant declaration. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers. More enterprise data, enterprise information, and enterprise development are all in the [Qichamao APP], the most cost-effective and most comprehensive enterprise query platform.